Aroa Biosurgery is taking the appropriate precautions and measures amid a rapidly changing global picture for COVID-19 virus.
CEO Brian Ward said; “We extend our thoughts to everyone affected by COVID-19. Our priority is ensuring our employees, contractors and customers are safe and protected from the spread of the virus. We will continue to make any necessary changes, and monitor the potential impacts of COVID-19 on our employees, customers and overall business, daily. At this stage we are not experiencing significant disruption or impact to the underlying production and marketing operations of our business and we continue to have adequate stock levels in market.”
As Aroa manufactures its products in New Zealand and also sources most of its raw materials there, we are not currently experiencing supply chain disruption.
Where supplementary raw materials are imported, these have been ordered proactively and alternative suppliers have been engaged, so that adequate stocks of raw material are available through to the end of 2020. We are currently operating our manufacturing facility at full capacity to provide contingency and increase stocks of our products. Aroa is also shipping in larger quantities to ensure that three months’ of stock is held at our San Diego distribution centre in the United States.
“We are committed to working closely with our customers, distribution partners, suppliers and our team to maintain continuity of supply of our soft tissue repair products through and beyond the duration of social and economic impacts of COVID-19,” Dr Ward said.
Please also note the following:
For US-based customers, Aroa Customer Services is available for any questions or concerns: 1-877-627-6224.